Drugs / Tetomilast

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 24 trials
Phase 2 NCT00874497 Mar 2009 → Jul 2015 chronic obstructive pulmonary disease Otsuka Pharmaceutical Development & Commercialization, Inc. Terminated No outcome recorded
Phase 2 NCT00917150 Mar 2009 → Apr 2014 chronic obstructive pulmonary disease Otsuka Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 2 NCT00317356 May 2006 → Aug 2007 ulcerative colitis Otsuka Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 2 NCT00317369 May 2006 → Jul 2007 Crohn disease Otsuka Pharmaceutical Co., Ltd. Terminated No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00989573 Oct 2009 → Aug 2012 Crohn disease Otsuka Pharmaceutical Co., Ltd. Completed No outcome recorded
Phase 33 trials
Phase 3 NCT00092508 May 2004 → May 2007 ulcerative colitis Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 3 NCT00064454 May 2003 → Jul 2006 ulcerative colitis Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded
Phase 3 NCT00064441 May 2003 → May 2006 ulcerative colitis Otsuka Pharmaceutical Development & Commercialization, Inc. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Tetomilast “OPC-6535(Tetomilast)” NCT00317356
3

“OPC-6535(Tetomilast)” NCT00317369

NCT00874497

NCT00917150

Known as OPC-6535 “tetomilast (OPC-6535)” NCT00917150
6

NCT00317356

NCT00092508

NCT00064454

NCT00317369

NCT00064441

NCT00989573

Modality Small molecule CHEMBL332750
Route Oral “once-daily oral administration” NCT00317356